Soki Kashima, MD, PhD
Postdoctoral AssociateAbout
Research
Publications
Featured Publications
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaTumor intrinsic featuresImmune checkpoint inhibitorsRobust predictive biomarkersCheckpoint inhibitorsDurable responsesOverall survivalCare regimensPathological characteristicsPredictive biomarkersTherapeutic responseTreatment paradigmImmune systemHost factorsTranscriptional signatureGenomic alterationsTumor heterogeneityBiomarkersCarcinomaBiomarker discoveryInnovative technological approachesRegimensThe Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaCentral therapeutic strategyAdvanced renal cancerDurable clinical benefitImmune checkpoint inhibitorsImmunecheckpoint inhibitorsCheckpoint inhibitorsCytokine therapyImmunogenic tumorsMost patientsSystemic therapyClinical benefitCombination therapyCurrent therapiesInterleukin-2Renal cancerTherapeutic strategiesTherapyCarcinomaInhibitorsImmunotherapyPatientsInterferonCytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model.
Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, DOI: 10.1016/j.isci.2020.100998.Peer-Reviewed Original ResearchRegeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.
Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Mol Ther Methods Clin Dev 2020, 19: 250-260. PMID: 33102617, DOI: 10.1016/j.omtm.2020.09.011.Peer-Reviewed Original ResearchFaithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol 2020, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y, Japanese Urological Oncology Group. Prognostic impact of histological discordance between transurethral resection and radical cystectomy. BJU Int 2024 PMID: 38344879, DOI: 10.1111/bju.16296.Peer-Reviewed Original Research
2023
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old. Int J Clin Oncol 2023, 28: 1530-1537. PMID: 37552353, DOI: 10.1007/s10147-023-02394-y.Peer-Reviewed Original ResearchPrimary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Kashima S, Yamamto R, Nara T, Akashi H, Tabata R, Sato S, Saito M, Narita S, Ohyama C, Habuchi T. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 2023, 12: 16837-16845. PMID: 37403728, DOI: 10.1002/cam4.6306.Peer-Reviewed Original ResearchImpact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Eur J Clin Pharmacol 2023, 79: 89-98. PMID: 36378297, DOI: 10.1007/s00228-022-03420-0.Peer-Reviewed Original ResearchASCO 2023 RECAP Combination Therapies Come of Age in Kidney Cancer
https://auanews.net/issues/articles/2023/october-extra-2023/asco-2023-recap-combination-therapies-come-of-age-in-kidney-cancerBooks
Academic Achievements & Community Involvement
News
News
- September 23, 2024Source: OncLive
Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 31, 2024
2024 ASCO Conquer Cancer Grants & Awards Announced
- April 04, 2024
Molecular Subtypes of Advanced Kidney Cancer Matter for Treatment Response